twitter Tweet

OHSU dermatologists detect the world’s smallest skin cancer

Guinness World Records recognizes the team that verified the world’s smallest skin cancer, OHSU leaders emphasize the importance of early cancer detection
Lea esta página en español
Joanna Ludzik, M.D., Ph.D., and Alexander Witkowski, M.D., Ph.D., receive official certification from Guinness World Records judge Alexander Glass as OHSU patient Christy Staats looks on. (OHSU/Christine Torres Hicks)
Joanna Ludzik, M.D., Ph.D., and Alexander Witkowski, M.D., Ph.D., receive official certification from Guinness World Records judge Andrew Glass as OHSU patient Christy Staats looks on. (OHSU/Christine Torres Hicks)

A tiny spot on Christy Staats’s cheek measured just 0.65 millimeters — or 0.025 inches — and was almost invisible to the human eye. But with help from state-of-the-art non-invasive technology, an OHSU dermatologist and a multi-disciplinary team confirmed the spot was indeed a melanoma, the most dangerous type of skin cancer.

Alexander Witkowski, M.D., Ph.D.
Alexander Witkowski, M.D., Ph.D. (Courtesy)

To identify this micro-skin cancer, Alexander Witkowski, M.D., Ph.D., an assistant professor of dermatology at the OHSU School of Medicine, used a combination of dermoscopy — an examination of skin lesions with a dermatoscope — and Reflectance Confocal Microscopy, which is an imaging tool that helps clinicians monitor and diagnose skin lesions without needing to cut into the skin. His colleagues Joanna Ludzik M.D., Ph.D., Jina Chung M.D., Sancy Leachman M.D., Ph.D., and Claudia Lee helped confirm the diagnosis by implementing additional staining and molecular testing techniques. 

Joanna Ludzick, M.D., Ph.D.
Joanna Ludzick, M.D., Ph.D. (Courtesy)

Catching this skin cancer early earned the OHSU team the Guinness World Record for the “Smallest Detected Skin Cancer.” On May 1, a judge from the Guinness World Records came to OHSU to award each team member a certificate for their newly-earned record.

This peer-reviewed and scientifically-validated skin cancer is a micro-melanoma in-situ, a type of cancer that is found exclusively on the top layer of the skin. Witkowski says this is important because “it was found before it had the opportunity to spread to other parts of the body.”

Sancy Leachman, M.D., Ph.D., (OHSU)
Sancy Leachman, M.D., Ph.D., (OHSU)

During the diagnostic process, the case was also reviewed by Giovanni Pellacani, M.D., president of the World Congress of Dermatology and chair of dermatology at La Sapienza University in Rome, Italy. Pellacani is a leading expert in Reflectance Confocal Microscopy and mentored both Witkowski and Ludzik — a husband and wife team — before they moved to the United States from Europe in 2019.

Right place, right time, right technology

Christy Staats had been watching a red spot on her face for several years. She saw several dermatologists, concerned about the spot underneath her eye, but was always told it was fine. After a few years, she stopped going to the dermatologist.

“During COVID, I started to think about my health a little more,” she says. “I have a magnifying mirror in my bathroom and noticed the spot I was worried about was way bigger and had a ‘leg’ on it. I set up an appointment to get it looked at.”

At that appointment, her dermatologist, Witkowski, examined the spot of concern. Witkowski’s examination revealed that the lesion she was worried about was actually a cherry angioma, a fairly common, benign, skin growth. However, during that evaluation, he noticed a tiny spot nearby on her right cheek — a spot that might not have otherwise been noticed — and he believed it warranted further evaluation.

“I took a picture of the spot with the Sklip smartphone attachment, then performed additional imaging with reflectance confocal microscopy (virtual biopsy) which showed atypical cells concerning for melanoma,” he says. “I told Christy right there at the bedside, ‘I think this could be the smallest skin cancer ever detected.’” 

The confocal microscope is used in-office and is placed on top of the skin to visualize cells underneath. It gives the physician the ability to see cells without having to cut into a patient’s skin. Witkowski says OHSU is one of the few centers in the country that have an in vivo confocal device — and the first one on the West Coast.

Witkowski then took a physical biopsy of the mole of concern, and the OHSU team evaluated it with pathology and molecular testing. Those results confirmed the diagnosis of an incredibly small melanoma in situ.  

“What our team accomplished together embodies my personal mission statement: ‘Catch the inevitable, early,’” says Witkowski.

Staats is grateful her melanoma was caught before it could grow or spread. She says she believes she was in the “right place at the right time…with the right technology.”

“I believe it is possible for everyone to be as lucky as me with the right technology,” she says. “If they can find mine when it’s so early, it is a no-brainer that this technology can help other people.”

She is also grateful she followed her instinct about her original spot of concern that led her to come in the office in the first place. “It’s an important reminder that you can’t get lazy with your skin. You have to stay on top of it and get new things checked out!”

The power of early cancer detection

The American Cancer Society estimates that in 2023, about 97,610 new melanomas will be diagnosed in the United States. Melanoma accounts for only about 1% of skin cancers overall, but causes a large majority of skin cancer deaths.  

Sancy Leachman, M.D., Ph.D., director of the OHSU Knight Cancer Institute’s Melanoma Program and chair of the Department of Dermatology in the OHSU School of Medicine says this case “truly demonstrates the power of new technology to identify potentially dangerous spots early.”

“With melanoma, your eyes really can be your best tool. A mole or spot on your skin that is changing in appearance — size, shape, coloration — is a key indicator for melanoma,” Leachman says. “The purchase of our confocal virtual biopsy device, which was so critical in diagnosing Christy’s early-stage melanoma, was made possible because of the successful completion of the $1 billion Knight Cancer Challenge in 2015. I’m so proud that we’re able to demonstrate what we can do with an investment in cancer early detection and research.”

“This was a team effort — we used skin imaging and technology to improve the early diagnosis of melanoma,” she says. “It took everyone on the team — dermatologists, dermatopathologists, and dermatologic surgeons. It’s an incredible thing when you have an entire team able to work together to help patients.”

May is Melanoma Awareness Month

May is national Skin Cancer/Melanoma Awareness month. To raise awareness about what people can do to check their skin, Leachman and team have started a public health campaign called “Start Seeing Melanoma,” which helps outline what to look for, how to properly do skin exams, and what to do if you find something suspicious.

Melanoma Awareness Month activities:

Oregon Check Your Skin Day – May 18

OHSU will once again commemorate “Oregon Check Your Skin Day,” an awareness day created to encourage people to check their skin for warning signs of skin cancer and take action by learning:

  • What to look for
  • How to do skin exams
  • What to do if you find something
  • Learn more at, a public health campaign created by Leachman and team.

“Steps Against Melanoma” statewide walks – May 21

  • OHSU is teaming up with AIM at Melanoma to host melanoma community walks in cities across Oregon on Sunday, May 21.
  • The walks will simultaneously take place in Portland, Bend, Prineville, Corvallis and Astoria to honor those who have been affected by melanoma while raising awareness and funds for research.
  • Learn more on the OHSU Dermatology website and register via Steps Against Melanoma Walk Oregon.

Disclosures: Witkowski and Ludzik are co-founders of Sklip, Inc., and have followed OHSU’s Conflict of Interest procedures. In the interest of ensuring the integrity of our research and as part of our commitment to public transparency, OHSU actively regulates, tracks and manages relationships that our researchers may hold with entities outside of OHSU. Review details of OHSU's conflict of interest program to find out more about how we manage these business relationships.

Leachman has a conflict of interest management plan requiring disclosure of an unrestricted educational gift from Castle Biosciences for the War on Melanoma™. 

Previous Story Media Event: OHSU clinical team to receive certification for detecting the world’s smallest skin cancer Next Story A surgeon-scientist blazes a new path to immune-based cancer treatment
Facebook Twitter LinkedIn YouTube Instagram OHSU Braille services OHSU sign language services OHSU interpreter services X